Prognostic risk factors in patients with bone metastasis from colorectal cancer
- 153 Downloads
The morbidity of bone metastasis (BM) from colorectal cancer (CRC) is increasing more than ever; however, insufficient research on BM from CRC leads to reduced awareness of the issue. Therefore, the aim of this study was to evaluate the clinical features and prognostic risk factors of CRC patients with BM. Clinical data were retrospectively analyzed for a total of 242 CRC patients with BM. Of the 242 CRC patients with BM, 52 (21.5 %) had bone metastasis alone (BMA) and 190 (78.5 %) had both bone and visceral metastasis (BM&VM). The median survival time (MST) after the diagnosis of BM in all 242 patients was 15.6 months (95 % confidence interval [CI] 12.74–18.46 months). The MST of the BMA group was significantly longer than that of the BM&VM group (29.1 vs. 12.8 months, p = 0.003). Using a Cox proportional hazard model, we identified a high carcinoembryonic antigen (CEA) level and BMA as independent prognostic factors for CRC patients with BM. For the BMA group, the independent prognostic factors were elevated alkaline phosphatase (ALP) and perineural invasion of the primary cancer, which were distinct from the factors for the entire group of BM patients. Furthermore, we found that the BMA patients with multiple sites of BM had similar prognosis to the BM&VM patients. These findings together provide us with a further understanding of BM from CRC and reveal that BMA may be a distinct subset of BM from CRC that has unique independent prognostic factors and a good prognosis.
KeywordsColorectal cancer Bone metastasis Prognosis Clinicopathological features
We thank all the patients whose data were used in this study. This work was supported by the National Natural Science Foundation of China (No. 81472620).
Compliance with ethical standards
Conflicts of interest
- 2.Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7.Google Scholar
- 3.Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society forGoogle Scholar
- 5.Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRefGoogle Scholar
- 6.Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRefGoogle Scholar
- 8.Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8.Google Scholar
- 14.Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7.Google Scholar